Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence

被引:15
|
作者
Dimosiari, Athina [1 ]
Patoulias, Dimitrios [1 ,2 ]
Kitas, George D. [3 ]
Dimitroulas, Theodoros [4 ]
机构
[1] European Interbalkan Med Ctr, Dept Internal Med 2, Thessaloniki 57001, Greece
[2] Aristotle Univ Thessaloniki, Gen Hosp Hippokrat, Outpatient Dept Cardiometab Med, Dept Cardiol 2, Thessaloniki 54642, Greece
[3] Dudley Grp NHS Fdn Trust, Russells Hall Hosp, Dept Rheumatol, Dudley DY1 2HQ, England
[4] Aristotle Univ Thessaloniki, Gen Hosp Hippokrat, Dept Internal Med 4, Thessaloniki 54642, Greece
关键词
cardiovascular disease; interleukin-1; interleukin-6; anakinra; canakinumab; tocilizumab; PERIPHERAL ARTERIAL-DISEASE; ALL-CAUSE MORTALITY; RHEUMATOID-ARTHRITIS; PROINFLAMMATORY CYTOKINES; MYOCARDIAL-INFARCTION; INFLAMMATORY MARKERS; CIRCULATING LEVELS; REACTIVE PROTEIN; HEART-FAILURE; RISK;
D O I
10.3390/jcm12041302
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular disease (CVD) constitutes a real pandemic of the 21st century. According to data from the Centers for Disease Control and Prevention, one person dies every 34 min due to some form of CVD in the United States. Apart from the extremely high morbidity and mortality accompanying CVD, the economic burden seems to be unbearable even for developed countries in the Western World. The role of inflammation in the development and progression of CVD appears to be crucial, while, various inflammatory pathways, such as the Nod-like receptor protein 3 (NLRP3) inflammasome-interleukin (IL)-1/IL-6 pathway of the innate immunity, have attracted scientific interest during the last decade, as a potential treatment target in primary and/or secondary prevention of CVD. Whereas there is a significant amount of evidence, stemming mainly from observational studies, concerning the cardiovascular safety of IL-1 and IL-6 antagonists in patients with rheumatic diseases, evidence from relevant randomized controlled trials (RCTs) is rather scarce and conflicting, especially for patients without underlying rheumatic disease. In this review, we summarize and critically present the currently available evidence, both from RCTs and observational studies, concerning the place that IL-1 and IL-6 antagonists may hold in the treatment of CVD.
引用
收藏
页数:16
相关论文
empty
未找到相关数据